Exact Sciences price target raised to $55 from $44 at Craig-Hallum

Craig-Hallum analyst Alex Nowak raised the firm’s price target on Exact Sciences to $55 from $44 and keeps a Hold rating on the shares. The firm notes that a better tone throughout 2022 led to a strong end to the year. Cologuard generated much better volume growth while Precision Oncology was largely in-line with Craig-Hallum’s original estimate.